Diasorin SpA (WBO:DIAS) Selling, General, & Admin. Expense: €241 Mil (TTM As of Dec. 2025)


WBO:DIAS Diasorin SpA WBO:DIAS
74 GF Score
Price €69.94
GF Value €90.02
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Diasorin SpA Selling, General, & Admin. Expense?

Diasorin SpA WBO:DIAS +5.17% 74 Selling, General, & Admin. Expense is €241 Mil as of Dec. 2025. GuruFocus rates WBO:DIAS with a GF Score™ of 74/100 and a GF Value™ of €90.02 (Modestly Undervalued). The stock has 5 warning signs investors should review.

Selling, general, & admin. expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. Diasorin SpA's selling, general, & admin. expense for the three months ended in Dec. 2025 was €60 Mil. Its selling, general, & admin. expense for the trailing twelve months (TTM) ended in Dec. 2025 was €241 Mil.


Diasorin SpA  (WBO:DIAS) Selling, General, & Admin. Expense Explanation

An efficient operation keeps SGA costs low and thus has higher profit margin. The percentage of SGA relative to total revenue is an indication of how efficiently the company operates. Compare this percentage among the companies in the same industry is a good way of finding more efficient operations. A comparison of the SGA cost relative to the revenue with the historical value can also be an indication of how efficient the company has become.

Warren Buffett likes companies with consistent SGA as the percentage of gross profit.

Companies with no durable competitive advantage show wild variation in SG&A as % of Gross Profit.

If SGA is less than 30% of Gross Profit, it is fantastic. If SGA is nearing 100%, it is is in highly competitive industry.


Diasorin SpA Selling, General, & Admin. Expense Related Terms


Diasorin SpA Selling, General, & Admin. Expense Historical Data

* Premium members only.

The historical data trend for Diasorin SpA's Selling, General, & Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Diasorin SpA Selling, General, & Admin. Expense Chart

Diasorin SpA Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Selling, General, & Admin. Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 296.34 364.79 368.13 376.14 364.18

Diasorin SpA Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Selling, General, & Admin. Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 103.00 81.89 99.00 60.18 0.00

WBO:DIAS vs TMO, DHR, IDXX: Selling, General, & Admin. Expense Comparison

For the Diagnostics & Research subindustry, Diasorin SpA's Selling, General, & Admin. Expense, along with its competitors' market caps and Selling, General, & Admin. Expense data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Diasorin SpA Selling, General, & Admin. Expense vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Diasorin SpA's Selling, General, & Admin. Expense distribution charts can be found below:

* The bar in red indicates where Diasorin SpA's Selling, General, & Admin. Expense falls into.


WBO:DIAS
74GF Score
Diasorin SpA WBO:DIAS
Selling, General, & Admin. Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Diasorin SpA Selling, General, & Admin. Expense Calculation

Selling, General, & Admin. Expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. For instance, personnel cost, advertising, rent, communication costs are all part of SGA.

Selling, General, & Admin. Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €241 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Selling, General, & Admin. Expense of €241 Mil mean?
Diasorin SpA (WBO:DIAS) has a Selling, General, & Admin. Expense of €241 Mil as of Dec. 2025. Selling, general and admin expense is the total cost for direct, indirect, general and administrative activities. View historical data on Diasorin SpA and its competitors.
Is Diasorin SpA's Selling, General, & Admin. Expense too high?
Diasorin SpA's current Selling, General, & Admin. Expense is €241 Mil. Overall, Diasorin SpA has a GF Score™ of 74/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Diasorin SpA's Selling, General, & Admin. Expense compare to TMO and DHR?
Diasorin SpA's Selling, General, & Admin. Expense of €241 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Selling, General, & Admin. Expense for a Medical Diagnostics & Research company?
A good Selling, General, & Admin. Expense depends on the Medical Diagnostics & Research industry context. However, Selling, General, & Admin. Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Selling, General, & Admin. Expense mean?
A high Selling, General, & Admin. Expense can signal that a stock is expensive relative to its fundamentals. Selling, general and admin expense is the total cost for direct, indirect, general and administrative activities. View historical data on Diasorin SpA and its competitors. Diasorin SpA's current Selling, General, & Admin. Expense is €241 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diasorin SpA stock overvalued right now?
Based on GuruFocus' analysis, Diasorin SpA (WBO:DIAS) is currently considered Modestly Undervalued. The stock's GF Value™ is €90.02, compared to a current price of €69.94 — trading 22.3% below its estimated fair value. The current Selling, General, & Admin. Expense is €241 Mil. Diasorin SpA's overall GF Score™ is 74/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Selling, General, & Admin. Expense calculated?
Selling, General, & Admin. Expense is calculated from a company's financial statements. For Diasorin SpA (WBO:DIAS), the current Selling, General, & Admin. Expense is €241 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Diasorin SpA (WBO:DIAS) Overvalued in 2026?

Based on GuruFocus' analysis, Diasorin SpA stock appears to be undervalued. The current stock price of €69.94 is trading 22.3% below its estimated GF Value™ of €90.02. GuruFocus considers Diasorin SpA to be Modestly Undervalued.

Key valuation signals for WBO:DIAS:

  • Selling, General, & Admin. Expense: €241 Mil
  • GF Value™: €90.02 vs. price of €69.94 (22.3% below fair value)
  • GF Score™: 74/100 with 5 warning signs

No single metric tells the full story. See the WBO:DIAS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Diasorin SpA Business Description

Address Via Crescentino Snc, Saluggia, Vercelli, ITA, 13040
Diasorin develops and manufactures a broad portfolio of in vitro diagnostics for detecting pathogens and sample contamination from the human body, as well as for use in industrial settings, such as food and water contamination testing. The company operates three segments: immunodiagnostics (69% of sales), molecular diagnostics (16%), and licensed technologies (14%). Diasorin was an important manufacturer of covid tests, which boosted its profits during the pandemic, but this segment's importance has decreased over the years, and in 2025, it accounted for only 1% of total sales.
74GF Score

Get the complete analysis for WBO:DIAS

Selling, General, & Admin. Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€69.94
Price
€90.02
GF Value